Background: Vascular risk factors (VRF) are associated with an increased risk of neurodegenerative disease.
Objective: To examine the association between VRF and cognitive decline in patients with Alzheimer’s disease (AD) and Lewy body dementia (LBD).
Methods: We included consecutive referrals with mild AD or LBD to dementia clinics in western Norway from 2005 to 2013. The Mini-Mental Status Exam (MMSE) and Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) were administered at baseline and then annually for up to five years. The VRF include diabetes mellitus, hypertension, hypercholesterolemia, overweight and smoking. Generalized Estimating Equations (GEE) were used to examine the potential association between VRF scores and the change in MMSE and CDR-SB scores, adjusting for age, sex, and the apolipoprotein ɛ4 allele (APOE4).
Results: A total of 200 patients were included (113 AD, 87 LBD) (mean age 76 years, mean baseline MMSE 24.0, mean follow-up time 3.5 years). Smoking was the only VRF significantly associated with a more rapid cognitive decline, however only in the AD group. Being overweight at baseline was associated with a slower cognitive decline. Moreover, hypertension at baseline predicted a slower decline in MMSE scores. In the LBD group diabetes mellitus was found to be associated with a slower increase in CDR-SB scores.
Conclusion: With the exception of smoking, VRF at time of dementia diagnosis were not associated with a more rapid cognitive decline.
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines, World Health Organization, Geneva.
2.
World Alzheimer Report (2009) The Global Prevalence of Dementia Alzheimer’s Disease International, London, UK.
3.
AarslandD, BallardC, HallidayG (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity?J Geriatr Psychiatry Neurol17, 137–145.
4.
SchmechelD, SaundersA, StrittmatterW, CrainBJ, HuletteCM, JooS, Pericak-VanceM, GoldgaberD, RosesAD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A90, 9649–9653.
5.
VijayaraghavanS, Darreh-ShoriT, RongveA, BergeG, SandoSB, WhiteLR, AuestadBH, WitoelarA, AndreassenOA, UlsteinID (2016) Association of butyrylcholinesterase-K allele and apolipoprotein E ɛ4 allele with cognitive decline in dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis50, 567–576.
6.
El-LebedyD, RaslanHM, MohammedAM (2016) Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol15, 12.
7.
de la TorreJC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol3, 184–190.
8.
RoselliF, TartaglioneB, FedericoF, LeporeV, DefazioG, LivreaP (2009) Rate of MMSE score change in Alzheimer’s disease: Influence of education and vascular risk factors. Clin Neurol Neurosurg111, 327–330.
9.
KivipeltoM, NganduT, FratiglioniL, ViitanenM, KåreholtI, WinbladB, HelkalaE-L, TuomilehtoJ, SoininenH, NissinenA (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol62, 1556–1560.
10.
KivipeltoM, HelkalaE-L, LaaksoMP, HänninenT, HallikainenM, AlhainenK, SoininenH, TuomilehtoJ, NissinenA (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population based study. BMJ322, 1447–1451.
11.
BretelerM, Van SwietenJ, BotsM, GrobbeeD, ClausJ, Van Den HoutJ, Van HarskampF, TangheH, De JongP, Van GijnJ (1994) Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study The Rotterdam Study. Neurology44, 1246–1246.
12.
DebetteS, MarkusH (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ341, c3666.
13.
BlomK, Emmelot-VonkMH, KoekHL (2013) The influence of vascular risk factors on cognitive decline in patients with dementia: A systematic review. Maturitas76, 113–117.
14.
RongveA, SoennesynH, SkogsethR, OesterhusR, HortobágyiT, BallardC, AuestadB, AarslandD (2016) Cognitive decline in dementia with Lewy bodies: A 5-year prospective cohort study. BMJ Open6, e010357.
15.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
16.
O’BryantSE, WaringSC, CullumCM, HallJ, LacritzL, MassmanPJ, LupoPJ, ReischJS, DoodyR (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer’s research consortium study. Arch Neurol65, 1091–1095.
17.
AarslandD, RongveA, Piepenstock NoreS, SkogsethR, SkulstadS, EhrtU, HoprekstadD, BallardC (2008) Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord26, 445–452.
18.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–939.
19.
McKeithI, DicksonDW, LoweJ, EmreM, O’brienJ, FeldmanH, CummingsJ, DudaJ, LippaC, PerryE (2005) Diagnosis and management of dementia with Lewy bodies third report of the DLB consortium. Neurology65, 1863–1872.
SoennesynH, OppedalK, GreveOJ, FritzeF, AuestadBH, NoreSP, BeyerMK, AarslandD (2012) White matter hyperintensities and the course of depressive symptoms in elderly people with mild dementia. Dement Geriatr Cogn Disord Extra2, 97–111.
22.
ScheltensP, BarkhofF, LeysD, PruvoJ, NautaJ, VermerschP, SteinlingM, ValkJ (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci114, 7–12.
BergeG, SandoSB, RongveA, AarslandD, WhiteLR (2014) Apolipoprotein E ɛ2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry85, 1227–1231.
25.
MontgomerySA, AsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134, 382–389.
26.
LeontjevasR, van HoorenS, MuldersA (2009) The Montgomery-Asberg Depression Rating Scale and the Cornell Scale for Depression in Dementia: A validation study with patients exhibiting early-onset dementia. Am J Geriatr Psychiatry17, 56–64.
HelznerEP, LuchsingerJA, ScarmeasN, CosentinoS, BrickmanAM, GlymourMM, SternY (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol66, 343–348.
29.
StaalsJ, MakinSD, DoubalFN, DennisMS, WardlawJM (2014) Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology83, 1228–1234.
30.
DickieDA, RitchieSJ, CoxSR, SakkaE, RoyleNA, AribisalaBS, HernándezMdCV, ManiegaSM, PattieA, CorleyJ (2016) Vascular risk factors and progression of white matter hyperintensities in the Lothian Birth Cohort 1936. Neurobiol Aging42, 116–123.
31.
TeipelS, GrotheMJ (2016) Association between smoking and cholinergic basal forebrain volume in healthy aging and prodromal and dementia stages of Alzheimer’s disease. J Alzheimers Dis52, 1443–1451.
32.
GorellJM, RybickiBA, JohnsonCC, PetersonEL (1999) Smoking and Parkinson’s disease A dose–response relationship. Neurology52, 115–115.
33.
AllamMF, CampbellMJ, HofmanA, Del CastilloAS, Fernández-Crehuet NavajasR (2004) Smoking andParkinson’s disease: Systematic review of prospective studies. Mov Disord19, 614–621.
34.
XuY, YangJ, ShangH (2016) Meta-analysis of risk factors for Parkinson’s disease dementia. Transl Neurodegener5, 1.
35.
AlvesG, KurzM, LieSA, LarsenJP (2004) Cigarette smoking in Parkinson’s disease: Influence on disease progression. Mov Disord19, 1087–1092.
36.
BootBP, OrrCF, AhlskogJE, FermanTJ, RobertsR, PankratzVS, DicksonDW, ParisiJ, AakreJA, GedaYE (2013) Risk factors for dementia with Lewy bodies A case-control study. Neurology81, 833–840.
37.
GlodzikL, RusinekH, KamerA, PirragliaE, TsuiW, MosconiL, LiY, McHughP, MurrayJ, WilliamsS (2016) Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimers Dement2, 95–104.
38.
KimS, KimY, ParkSM (2016) Body mass index and decline of cognitive function. PLoS One11, e0148908.
39.
BesserLM, GillDP, MonsellSE, BrenowitzW, MeranusD, KukullW, GustafsonDR (2014) Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer’s disease. Alzheimer Dis Assoc Disord28, 36.
40.
SoysalP, IsikAT, StubbsB, SolmiM, VolpeM, LuchiniC, D’OnofrioG, PilottoA, ManzatoE, SergiG (2016) Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2016-313660
CoinA, VeroneseN, De RuiM, MoseleM, BolzettaF, GirardiA, ManzatoE, SergiG (2012) Nutritional predictors of cognitive impairment severity in demented elderly patients: The key role of BMI. J Nutr Health Aging16, 553–556.
43.
FitzpatrickAL, LopezOL, KullerLH (2006) Mid- and late life obesity: Risk of dementia in the Cardiovascular Health Cognition Study. Ann Neurol60, S4.
44.
StrandbergTE, StrandbergAY, SalomaaVV, PitkäläKH, TilvisRS, SirolaJ, MiettinenTA (2009) Explaining the obesity paradox: Cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J30, 1720–1727.
BlomK, VaartjesI, PetersSA, KoekHL (2014) The influence of vascular risk factors on cognitive decline in patients with Alzheimer’s disease. Maturitas79, 96–99.
47.
BarberR, ScheltensP, GholkarA, BallardC, McKeithI, InceP, PerryR, O’brienJ (1999) White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry67, 66–72.
48.
HaugarvollK, AarslandD, Wentzel-LarsenT, LarsenJ (2005) The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol Scand112, 386–390.
49.
GhebremedhinE, RosenbergerA, RübU, VuksicM, BerheT, BickeböllerH, de VosRA, ThalDR, DellerT (2010) Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. J Neuropathol Exp Neurol69, 442–448.
DeschaintreY, RichardF, LeysD, PasquierF (2009) Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology73, 674–680.
52.
U.S. Preventive Services Task Force (2007) Screening for high blood pressure: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med147, 783–786.
53.
PanzaF, D’IntronoA, ColaciccoAM, CapursoC, PichicheroG, CapursoSA, CapursoA, SolfrizziV (2006) Lipid metabolism in cognitive decline and dementia. Brain Res Rev51, 275–292.
